← All trials
NCT04672824
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Dec 17, 2020
- Last posted
- Dec 17, 2020
- Enrollment
- 30
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OxfordLead sponsor
- Medical Research Council-UVRI Uganda Research Unit on AIDSCollaborator
- Medical Research Council-UVRI Uganda Research Unit on AIDSOverall official - principal investigator
- Medical Research Council-UVRI Uganda Research Unit on AIDSCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.